Clinical Trials Browser

NCT00492999 2026-06-03

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2 Active not recruiting

64 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT05329766 2026-06-02

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05836584 2026-05-28

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2 Active not recruiting

240 enrolled

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

11 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06094140 2026-05-06

NEO-IMPACT

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2 Active not recruiting

252 enrolled

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

176 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05009069 2026-04-21

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

58 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Clinical Stage 0 Gastric Cancer AJCC v8

NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Phase 2 Active not recruiting

50 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03323463 2026-04-13

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Phase 2 Active not recruiting

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Phase 2 Active not recruiting

43 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

Phase 2 Active not recruiting

320 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

143 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT04245865 2026-04-03

Toco-CoR

Phase 2 Active not recruiting

83 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2 Active not recruiting

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05466799 2026-02-13

TRIPP-FFX

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Locally Advanced Pancreatic Cancer

NCT06268015 2026-02-05

BBOpCo

Phase 2 Active not recruiting

16 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04762953 2026-02-03

STOPGAP

Phase 2 Active not recruiting

40 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Phase 2 Active not recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT00335816 2026-01-14

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2 Active not recruiting

248 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Phase 2 Active not recruiting

12 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

42 enrolled 13 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05504252 2026-01-07

METIMMOX-2

Phase 2 Active not recruiting

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

328 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2 Active not recruiting

280 enrolled

Tumor-Agnostic

Neoplasms

NCT05843188 2025-12-09

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

Phase 2 Active not recruiting

155 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05382442 2025-10-14

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Phase 2 Active not recruiting

254 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05699603 2025-09-24

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Phase 2 Active not recruiting

56 enrolled

Dermatologic

Keratosis, Actinic

NCT03110926 2025-09-12

Induction Chemotherapy for Locally Advanced Esophageal Cancer

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

46 enrolled

Genitourinary

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT05610163 2025-09-08

JANUS

Phase 2 Active not recruiting

783 enrolled

Gastrointestinal

Rectal Neoplasms

NCT02008656 2025-08-27

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Phase 2 Active not recruiting

358 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Phase 2 Active not recruiting

146 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase 2 Active not recruiting

172 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03421288 2025-07-25

DANTE

Phase 2 Active not recruiting

677 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03806309 2025-07-25

TEDOPAM

Phase 2 Active not recruiting

106 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05253846 2025-06-10

ShorTrip

Phase 2 Active not recruiting

63 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT03073785 2025-05-25

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Phase 2 Active not recruiting

46 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

1,460 enrolled

Breast

Breast Neoplasms

NCT03018418 2024-09-19

Proton Therapy in Reducing Toxicity in Anal Cancer

Phase 2 Active not recruiting

14 enrolled 14 charts

Gastrointestinal

Anus Neoplasms

NCT04230759 2024-09-19

RADIANCE

Phase 2 Active not recruiting

180 enrolled

Gastrointestinal

Anus Neoplasms